IL146399A0 - Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells - Google Patents
Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cellsInfo
- Publication number
- IL146399A0 IL146399A0 IL14639900A IL14639900A IL146399A0 IL 146399 A0 IL146399 A0 IL 146399A0 IL 14639900 A IL14639900 A IL 14639900A IL 14639900 A IL14639900 A IL 14639900A IL 146399 A0 IL146399 A0 IL 146399A0
- Authority
- IL
- Israel
- Prior art keywords
- nucleic acid
- delivering
- cells
- antibody conjugate
- foreign
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9905943A FR2793414B1 (en) | 1999-05-10 | 1999-05-10 | NUCLEIC ACID-ANTIBODY CONJUGATE FOR DELIVERING FOREIGN NUCLEIC ACID TO CELLS |
PCT/FR2000/001259 WO2000067697A2 (en) | 1999-05-10 | 2000-05-10 | Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
Publications (1)
Publication Number | Publication Date |
---|---|
IL146399A0 true IL146399A0 (en) | 2002-07-25 |
Family
ID=9545418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14639900A IL146399A0 (en) | 1999-05-10 | 2000-05-10 | Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1175498A2 (en) |
JP (1) | JP2002543810A (en) |
AU (1) | AU4415200A (en) |
CA (1) | CA2373851A1 (en) |
FR (1) | FR2793414B1 (en) |
IL (1) | IL146399A0 (en) |
WO (1) | WO2000067697A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2514536A1 (en) * | 2003-01-31 | 2004-08-12 | Novartis Ag | Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes |
JP4521519B2 (en) * | 2003-05-26 | 2010-08-11 | 学校法人慶應義塾 | Partial histone tail type immunoporter |
FR2958645B1 (en) * | 2010-04-09 | 2012-08-31 | Commissariat Energie Atomique | HEMI-ANTIBODY WITH SELF-ASSEMBLY |
US10540907B2 (en) | 2014-07-31 | 2020-01-21 | Intelligent Technologies International, Inc. | Biometric identification headpiece system for test taking |
US9959777B2 (en) | 2014-08-22 | 2018-05-01 | Intelligent Technologies International, Inc. | Secure testing device, system and method |
US10410535B2 (en) | 2014-08-22 | 2019-09-10 | Intelligent Technologies International, Inc. | Secure testing device |
WO2016073202A1 (en) | 2014-11-04 | 2016-05-12 | Intelligent Technologies International, Inc. | Smartcard |
CN108530540B (en) * | 2018-03-30 | 2021-06-15 | 华南农业大学 | Anti-spermidine monoclonal antibody hybridoma cell strain 4E4, monoclonal antibody thereof and application |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
EP0366707A1 (en) * | 1987-05-06 | 1990-05-09 | OOSTERWIJK, Egbert | Monoclonal antibodies to renal cell carcinoma |
US5428132A (en) * | 1987-10-11 | 1995-06-27 | United States Of America | Conjugate and method for integration of foreign DNA into cells |
IL106760A (en) * | 1992-08-25 | 1999-12-31 | Miles Inc | Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus |
US5574142A (en) * | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
IL112372A (en) * | 1994-02-07 | 2001-08-26 | Res Dev Foundation | Non-viral vector for the delivery of genetic information to cells |
WO1996013599A1 (en) * | 1994-11-01 | 1996-05-09 | Winfried Wels | Nucleic acid transfer system |
GB9614699D0 (en) * | 1996-07-12 | 1996-09-04 | John P Robarts Research Inst T | Hybrid herpes virus-based vector for gene delivery and expression |
DE19717904A1 (en) * | 1997-04-23 | 1998-10-29 | Diagnostikforschung Inst | Acid-labile and enzymatically cleavable dye constructs for diagnostics with near infrared light and for therapy |
EP0989864A1 (en) * | 1997-06-11 | 2000-04-05 | The School Of Pharmacy, University Of London | Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs |
-
1999
- 1999-05-10 FR FR9905943A patent/FR2793414B1/en not_active Expired - Fee Related
-
2000
- 2000-05-10 IL IL14639900A patent/IL146399A0/en unknown
- 2000-05-10 WO PCT/FR2000/001259 patent/WO2000067697A2/en active Search and Examination
- 2000-05-10 CA CA002373851A patent/CA2373851A1/en not_active Abandoned
- 2000-05-10 AU AU44152/00A patent/AU4415200A/en not_active Abandoned
- 2000-05-10 JP JP2000616728A patent/JP2002543810A/en active Pending
- 2000-05-10 EP EP00925426A patent/EP1175498A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2000067697A2 (en) | 2000-11-16 |
FR2793414A1 (en) | 2000-11-17 |
FR2793414B1 (en) | 2003-05-23 |
JP2002543810A (en) | 2002-12-24 |
WO2000067697A3 (en) | 2001-06-28 |
CA2373851A1 (en) | 2000-11-16 |
AU4415200A (en) | 2000-11-21 |
EP1175498A2 (en) | 2002-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1052801A1 (en) | High-efficiency fuel cell system | |
EP1229603A4 (en) | Lithium cell | |
GB9826127D0 (en) | Improvements in battery chargers | |
IL146399A0 (en) | Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells | |
EP1176191A4 (en) | Alpha-glycated amino acid releasing enzyme | |
AU2001283287A1 (en) | Method for distributing electrolyte in batteries | |
GB0004540D0 (en) | Interconnects for solid oxide fuel cells | |
EP1128451A4 (en) | Cell | |
IL131842A0 (en) | Chargeable electrochemical cell | |
AU2001244743A1 (en) | Fuel for use in fuel cell system | |
GB2347140B (en) | Storage cells | |
GB9917564D0 (en) | Improvements in refining | |
HUP0203314A3 (en) | Oleoyl-acyl-carrier-protein thioesterases in plants | |
AU5658301A (en) | A particulate complex for administering nucleic acid into a cell | |
GB2355348B (en) | Improvements in connectors | |
AU6509200A (en) | Purine metabolism genes in plants | |
GB9908788D0 (en) | Gene expression in eukaryotic cells | |
GB9921418D0 (en) | Cell transfection | |
AU5706100A (en) | Animal defective in uti gene function | |
AU2001267883A1 (en) | Fuel for use in fuel cell system | |
IL132620A (en) | Arrangement of cells in a stack | |
GB9914764D0 (en) | Improvements in rolling pins | |
TW379587U (en) | Structural improvement in dice-shaking cup | |
AU2003203672A1 (en) | Methods for promoting cell transfection in vivo | |
GB2353817B (en) | Improvements in or relating to a support arrangement |